We also demonstrated that elevation of plasma IP-10 (CXCL10), a key chemoattractant for activated CD8+ T cells that was detected in our preclinical models, was observed in patients with PTCL after tolinapant treatment. This evidence concerns the gene CXCL10 and mature T-cell and NK-cell non-Hodgkin lymphoma.